Cytochrome P450 pharmacogenetics in African populations

References

• Abdel-Rahman SZ, Anwar WA, Abdel-Aal WE, et al. (1997). The CYP2D6 extensive metabolizer genotype is associated with increased risk for bladder cancer. Cancer Lett 119:115–122
   PubMed Web of Science ®Google Scholar
• Achour A, Zaag I, Gueddah L, et al. (2011). Role of CYP1A1 (T6235C) polymorphism and cigarette smoking in the development of coronary heart disease in Tunisian population. J Genet 90:303–307
   PubMed Web of Science ®Google Scholar
• Adjei GO, Kristensen K, Goka BQ, et al. (2008). Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria. Antimicrob Agents Chemother 52:4400–4406
   PubMed Web of Science ®Google Scholar
• Aklillu E, Carrillo JA, Makonnen E, et al. (2003). Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: Characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol 64:659–669
   PubMed Web of Science ®Google Scholar
• Aklillu E, Herrlin K, Gustafsson LL, et al. (2002). Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. Pharmacogenetics 12:375–383
   PubMedGoogle Scholar
• Aklillu E, Persson I, Bertilsson L, et al. (1996). Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 278:441–446
   PubMed Web of Science ®Google Scholar
• Allabi AC, Gala JL, Desager JP, et al. (2003). Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br J Clin Pharmacol 56:653–657
   PubMed Web of Science ®Google Scholar
• Allabi AC, Gala JL, Horsmans Y. (2005). CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics 15:779–786
   PubMed Web of Science ®Google Scholar
• Anwar WA, Abdel-Rahman SZ, EL-Zein RA, et al. (1996). Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients. Carcinogenesis 17:1923–1929
   PubMed Web of Science ®Google Scholar
• Babalola CP, Adejumo O, Ung D, et al. (2010). Cytochrome P450 CYP2C19 genotypes in Nigerian sickle-cell disease patients and normal controls. J Clin Pharm Ther 35:471–477
   PubMed Web of Science ®Google Scholar
• Bathum L, Skjelbo E, Mutabingwa TK, et al. (1999). Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. Br J Clin Pharmacol 48:395–401
   PubMed Web of Science ®Google Scholar
• B'Chir F, Pavanello S, Knani J, et al. (2009). CYP1A2 genetic polymorphisms and adenocarcinoma lung cancer risk in the Tunisian population. Life Sci 84:779–784
   PubMed Web of Science ®Google Scholar
• Blaisdell J, Jorge-Nebert LF, Coulter S, et al. (2004). Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 14:527–537
   PubMedGoogle Scholar
• Blaisdell J, Mohrenweiser H, Jackson J, et al. (2002). Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics 12:703–711
   PubMedGoogle Scholar
• Bolaji OO, Sadare IO, Babalola CP, Ogunbona FA. (2002). Polymorphic oxidative metabolism of proguanil in a Nigerian population. Eur J Clin Pharmacol 58:543–545
   PubMed Web of Science ®Google Scholar
• Bolt HM, Roos PH, Thier R. (2003). The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: Consequences for occupational and environmental medicine. Int Arch Occup Environ Health 76:174–185
   PubMed Web of Science ®Google Scholar
• Bradford LD. (2002). CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3:229–243
   PubMed Web of Science ®Google Scholar
• Burk O, Tegude H, Koch I, et al. (2002). Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J Biol Chem 277:24280–24288
   PubMed Web of Science ®Google Scholar
• Cavaco I, Reis R, Gil JP, Ribeiro V. (2003). CYP3A4*1B and NAT2*14 alleles in a native African population. Clin Chem Lab Med 41:606–609
   PubMed Web of Science ®Google Scholar
• Cavaco I, Stromberg-Norklit J, Kaneko A, et al. (2005). CYP2C8 polymorphism frequencies among malaria patients in Zanzibar. Eur J Clin Pharmacol 61:15–18
   PubMed Web of Science ®Google Scholar
• Cavallari LH, Langaee TY, Momary KM, et al. (2010). Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther 87:459–464
   PubMed Web of Science ®Google Scholar
• Chelule PK, Gordon M, Palanee T, et al. (2003). MDR1 and CYP3A4 polymorphisms among African, Indian, and white populations in KwaZulu-Natal, South Africa. Clin Pharmacol Ther 74:195–196
   PubMed Web of Science ®Google Scholar
• Chelule PK, Pegoraro RJ, Gqaleni N, Dutton MF. (2006). The frequency of cytochrome P450 2E1 polymorphisms in Black South Africans. Dis Markers 22:351–354
   PubMed Web of Science ®Google Scholar
• Cohen K, Grant A, Dandara C, et al. (2009). Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther 14:687–695
   PubMed Web of Science ®Google Scholar
• Cote ML, Wenzlaff AS, Bock CH, et al. (2007). Combinations of cytochrome P-450 genotypes and risk of early-onset lung cancer in Caucasians and African Americans: A population-based study. Lung Cancer 55:255–262
   PubMed Web of Science ®Google Scholar
• Crews KR, Gaedigk A, Dunnenberger HM, et al. (2012). Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther 91:321–326
   PubMed Web of Science ®Google Scholar
• Csajka C, Marzolini C, Fattinger K, et al. (2003). Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther 73:20–30
   PubMed Web of Science ®Google Scholar
• Dai D, Zeldin DC, Blaisdell JA, et al. (2001). Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11:597–607
   PubMedGoogle Scholar
• Dandara C, Ballo R, Parker MI. (2005). CYP3A5 genotypes and risk of oesophageal cancer in two South African populations. Cancer Lett 225:275–282
   PubMed Web of Science ®Google Scholar
• Dandara C, Basvi PT, Bapiro TE, et al. (2004). Frequency of -163 C>A and 63 C>G single nucleotide polymorphism of cytochrome P450 1A2 in two African populations. Clin Chem Lab Med 42:939–941
   PubMed Web of Science ®Google Scholar
• Dandara C, Lombard Z, DU Plooy I, et al. (2011). Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: A window into diversity. Pharmacogenomics 12:1663–1670
   PubMed Web of Science ®Google Scholar
• Dandara C, Masimirembwa CM, Magimba A, et al. (2001). Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients. Eur J Clin Pharmacol 57:11–17
   PubMed Web of Science ®Google Scholar
• de Wit E, Delport W, Rugamika CE, et al. (2010). Genome-wide analysis of the structure of the South African Coloured Population in the Western Cape. Hum Genet 128:145–153
   PubMed Web of Science ®Google Scholar
• Dandara C, Sayi J, Masimirembwa CM, et al. (2002). Genetic polymorphism of cytochrome P450 1A1 (CYP1A1) and glutathione transferases (M1, T1 and P1) among Africans. Clin Chem Lab Med 40:952–957
   PubMed Web of Science ®Google Scholar
• Di Iulio J, Fayet A, Arab-Alameddine M, et al. (2009). In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics 19:300–309
   PubMed Web of Science ®Google Scholar
• Drogemoller BI, Wright GE, Niehaus DJ, et al. (2010). Characterization of the genetic profile of CYP2C19 in two South African populations. Pharmacogenomics 11:1095–1103
   PubMed Web of Science ®Google Scholar
• Droll K, Bruce-Mensah K, Otton SV, et al. (1998). Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. Pharmacogenetics 8:325–333
   PubMedGoogle Scholar
• Ebeshi BU, Bolaji OO, Masimirembwa C. (2011). Cytochrome P450 2D6 (CYP2D6) genotype and phenotype determination in the Nigerian population. Asian J Pharm Hea Sci 1:47--54
   Google Scholar
• Edeki TI, Goldstein JA, DE Morais SM, et al. (1996). Genetic polymorphism of S-mephenytoin 4′-hydroxylation in African-Americans. Pharmacogenetics 6:357–360
   PubMedGoogle Scholar
• Elens L, Bouamar R, Hesselink DA, et al. (2011a). A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem 57:1574–1583
   PubMed Web of Science ®Google Scholar
• Elens L, Van Schaik RH, Panin N, et al. (2011b). Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics 12:1383–1396
   PubMed Web of Science ®Google Scholar
• Fernandez P, De Beer PM, Van Der Merwe L, Heyns CF. (2010). Genetic variations in androgen metabolism genes and associations with prostate cancer in South African men. S Afr Med J 100:741–745
   PubMed Web of Science ®Google Scholar
• Ferreira PE, Veiga MI, Cavaco I, et al. (2008). Polymorphism of antimalaria drug metabolizing, nuclear receptor, and drug transport genes among malaria patients in Zanzibar, East Africa. Ther Drug Monit 30:10–15
   PubMed Web of Science ®Google Scholar
• Fukami T, Nakajima M, Yoshida R, et al. (2004). A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. Clin Pharmacol Ther 76:519–527
   PubMed Web of Science ®Google Scholar
• Gaedigk A, Bhathena A, Ndjountche L, et al. (2005). Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans. Pharmacogenomics J 5:173–182
   PubMed Web of Science ®Google Scholar
• Gaedigk A, Bradford LD, Marcucci KA, Leeder JS. (2002). Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther 72:76–89
   PubMed Web of Science ®Google Scholar
• Gaedigk A, Coetsee C. (2008). The CYP2D6 gene locus in South African Coloureds: Unique allele distributions, novel alleles and gene arrangements. Eur J Clin Pharmacol 64:465–475
   PubMed Web of Science ®Google Scholar
• Gaedigk A, Ndjountche L, Gaedigk R, et al. (2003). Discovery of a novel nonfunctional cytochrome P450 2D6 allele, CYP2D642, in African American subjects. Clin Pharmacol Ther 73:575–576
   PubMed Web of Science ®Google Scholar
• Gaedigk A, Simon SD, Pearce RE, et al. (2008). The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 83:234–242
   PubMed Web of Science ®Google Scholar
• Garcia-Martin E, Martinez C, Ladero JM, Agundez JA. (2006). Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther 10:29–40
   PubMed Web of Science ®Google Scholar
• Garsa AA, McLeod HL, Marsh S. (2005). CYP3A4 and CYP3A5 genotyping by Pyrosequencing. BMC Med Genet 6:19
   PubMed Web of Science ®Google Scholar
• Garte S. (1998). The role of ethnicity in cancer susceptibility gene polymorphisms: The example of CYP1A1. Carcinogenesis 19:1329–1332
   PubMed Web of Science ®Google Scholar
• Garte S, Gaspari L, Alexandrie AK, et al. (2001). Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 10:1239–1248
   PubMed Web of Science ®Google Scholar
• Garte SJ, Trachman J, Crofts F, et al. (1996). Distribution of composite CYP1A1 genotypes in Africans, African-Americans and Caucasians. Hum Hered 46:121–127
   PubMed Web of Science ®Google Scholar
• Gellner K, Eiselt R, Hustert E, et al. (2001). Genomic organization of the human CYP3A locus: Identification of a new, inducible CYP3A gene. Pharmacogenetics 11:111--121
   PubMedGoogle Scholar
• Gervasini G, Vizcaino S, Gasiba C, et al. (2005). Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and Other Caucasian populations. Ther Drug Monit 27:819–821
   PubMed Web of Science ®Google Scholar
• Goldstein JA. (2001). Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 52:349–355
   PubMed Web of Science ®Google Scholar
• Gonzalez FJ, Gelboin HV. (1994). Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev 26:165–183
   PubMed Web of Science ®Google Scholar
• Gounden V, Van Niekerk C, Snyman T, George JA. (2010). Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. AIDS Res Ther 7:32
   PubMed Web of Science ®Google Scholar
• Griese EU, Asante-Poku S, Ofori-Adjei D, et al. (1999). Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population. Pharmacogenetics 9:715–723
   PubMedGoogle Scholar
• Gross R, Aplenc R, Tenhave T, et al. (2008). Slow efavirenz metabolism genotype is common in Botswana. J Acquir Immune Defic Syndr 49:336–337
   PubMed Web of Science ®Google Scholar
• Guengerich FP, Hosea NA, Parikh A, et al. (1998). Twenty years of biochemistry of human P450s: Purification, expression, mechanism, and relevance to drugs. Drug Metab Dispos 26:1175–1178
   PubMed Web of Science ®Google Scholar
• Gunes A, Dahl ML. (2008). Variation in CYP1A2 activity and its clinical implications: Influence of environmental factors and genetic polymorphisms. Pharmacogenomics 9:625–637
   PubMed Web of Science ®Google Scholar
• Gyamfi MA, Fujieda M, Kiyotani K, et al. (2005). High prevalence of cytochrome P450 2A6*1A alleles in a black African population of Ghana. Eur J Clin Pharmacol 60:855–857
   PubMed Web of Science ®Google Scholar
• Haas DW, Bartlett JA, Andersen JW, et al. (2006). Pharmacogenetics of nevirapine-associated hepatotoxicity: An Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis 43:783–786
   PubMed Web of Science ®Google Scholar
• Haas DW, Ribaudo HJ, Kim RB, et al. (2004). Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group study. AIDS 18:2391–2400
   PubMed Web of Science ®Google Scholar
• Hamdy SI, Hiratsuka M, Narahara K, et al. (2002). Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol 53:596–603
   PubMed Web of Science ®Google Scholar
• Hamdy SI, Hiratsuka M, Narahara K, et al. (2003). Genotyping of four genetic polymorphisms in the CYP1A2 gene in the Egyptian population. Br J Clin Pharmacol 55:321–324
   PubMed Web of Science ®Google Scholar
• He P, Court MH, Greenblatt DJ, Von Moltke LL. (2005). Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin Pharmacol Ther 77:373–387
   PubMed Web of Science ®Google Scholar
• Herrlin K, Massele AY, Jande M, et al. (1998). Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin Pharmacol Ther 64:391–401
   PubMed Web of Science ®Google Scholar
• Hu Y, Oscarson M, Johansson I, et al. (1997). Genetic polymorphism of human CYP2E1: Characterization of two variant alleles. Mol Pharmacol 51:370–376
   PubMed Web of Science ®Google Scholar
• Huang JD, Guo WC, Lai MD, et al. (1999). Detection of a novel cytochrome P-450 1A2 polymorphism (F21L) in Chinese. Drug Metab Dispos 27:98–101
   PubMed Web of Science ®Google Scholar
• Ikediobi O, Aouizerat B, Xiao Y, et al. (2011). Analysis of pharmacogenetic traits in two distinct South African populations. Hum Genomics 5:265–282
   PubMedGoogle Scholar
• Ingelman-Sundberg M, Oscarson M, McLellan RA. (1999). Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment. Trends Pharmacol Sci 20:342–349
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. (2007). Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496–526
   PubMed Web of Science ®Google Scholar
• Inoue K, Asao T, Shimada T. (2000). Ethnic-related differences in the frequency distribution of genetic polymorphisms in the CYP1A1 and CYP1B1 genes in Japanese and Caucasian populations. Xenobiotica 30:285–295
   PubMed Web of Science ®Google Scholar
• Iyun AO, Lennard MS, Tucker GT, Woods HF. (1986). Metoprolol and debrisoquin metabolism in Nigerians: Lack of evidence for polymorphic oxidation. Clin Pharmacol Ther 40:387–394
   PubMed Web of Science ®Google Scholar
• Iyun AO, Tucker GT, Woods HF, Lennard MS. (1990). The 4-hydroxylation of S-mephenytoin in Nigerians: A population study. Br J Clin Pharmacol 30:312P (abstract)
   Google Scholar
• Jamshidi Y, Moreton M, Mckeown DA, et al. (2010). Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: Implications for efavirenz dosing in HIV infection. J Antimicrob Chemother 65:2614–2619
   PubMed Web of Science ®Google Scholar
• Jiang Z, Dalton TP, Jin L, et al. (2005). Toward the evaluation of function in genetic variability: Characterizing human SNP frequencies and establishing BAC-transgenic mice carrying the human CYP1A1_CYP1A2 locus. Hum Mutat 25:196–206
   PubMed Web of Science ®Google Scholar
• Johnson JA, Gong L, Whirl-Carrillo M, et al. (2011). Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 90:625–629
   PubMed Web of Science ®Google Scholar
• Kato S, Shields PG, Caporaso NE, et al. (1992). Cytochrome P450IIE1 genetic polymorphisms, racial variation, and lung cancer risk. Cancer Res 52:6712–6715
   PubMed Web of Science ®Google Scholar
• Kisselev P, Schunck WH, Roots I, Schwarz D. (2005). Association of CYP1A1 polymorphisms with differential metabolic activation of 17beta-estradiol and estrone. Cancer Res 65:2972–2978
   PubMed Web of Science ®Google Scholar
• Kittles RA, Chen W, Panguluri RK, et al. (2002). CYP3A4-V and prostate cancer in African Americans: Causal or confounding association because of population stratification? Hum Genet 110:553–560
   PubMed Web of Science ®Google Scholar
• Klein K, Lang T, Saussele T, et al. (2005). Genetic variability of CYP2B6 in populations of African and Asian origin: Allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 15:861–873
   PubMed Web of Science ®Google Scholar
• Kudzi W, Dodoo AN, Mills JJ. (2009). Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. BMC Med Genet 10:124
   PubMed Web of Science ®Google Scholar
• Kudzi W, Dodoo AN, Mills JJ. (2010). Genetic polymorphisms in MDR1, CYP3A4 and CYP3A5 genes in a Ghanaian population: A plausible explanation for altered metabolism of ivermectin in humans? BMC Med Genet 11:111
   PubMed Web of Science ®Google Scholar
• Kuehl P, Zhang J, Lin Y, et al. (2001). Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383–391
   PubMed Web of Science ®Google Scholar
• Kwara A, Lartey M, Sagoe KW, et al. (2009). CYP2B6 (c.516G–>T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. Br J Clin Pharmacol 67:427–436
   PubMed Web of Science ®Google Scholar
• Lakhman SS, MA Q, Morse GD. (2009). Pharmacogenomics of CYP3A: Considerations for HIV treatment. Pharmacogenomics 10:1323–1339
   PubMed Web of Science ®Google Scholar
• Lamba JK, Lin YS, Thummel K, et al. (2002). Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 12:121–132
   PubMedGoogle Scholar
• Leathart JB, London SJ, Steward A, et al. (1998). CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics 8:529–541
   PubMedGoogle Scholar
• Leeder JS, Gaedigk R, Marcucci KA, et al. (2005). Variability of CYP3A7 expression in human fetal liver. J Pharmacol Exp Ther 314:626–635
   PubMed Web of Science ®Google Scholar
• Lennard MS, Iyun AO, Jackson PR, et al. (1992). Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians. Pharmacogenetics 2:89–92
   PubMedGoogle Scholar
• Li D, Dandara C, Parker MI. (2005). Association of cytochrome P450 2E1 genetic polymorphisms with squamous cell carcinoma of the oesophagus. Clin Chem Lab Med 43:370–375
   PubMed Web of Science ®Google Scholar
• Lim JS, Chen XA, Singh O, et al. (2011). Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. Br J Clin Pharmacol 71:737–750
   PubMed Web of Science ®Google Scholar
• Lim JS, Singh O, Ramasamy RD, et al. (2010). Pharmacogenetics of CYP1A2, novel polymorphisms and haplotypes in three distinct Asian populations. Drug Metab Pharmacokinet 25:616–623
   PubMed Web of Science ®Google Scholar
• Luo HR, Aloumanis V, Lin KM, et al. (2004). Polymorphisms of CYP2C19 and CYP2D6 in Israeli ethnic groups. Am J Pharmacogenomics 4:395–401
   PubMedGoogle Scholar
• Maimbo M, Kiyotani K, Mushiroda T, et al. (2012). CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans. Eur J Clin Pharmacol 68:267–271
   PubMed Web of Science ®Google Scholar
• Marez D, Legrand M, Sabbagh N, et al. (1997). Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7:193–202
   PubMedGoogle Scholar
• Marsh S, King CR, Porche-Sorbet RM, et al. (2006). Population variation in VKORC1 haplotype structure. J Thromb Haemost 4:473–474
   PubMed Web of Science ®Google Scholar
• Masimirembwa CM, Beke M, Hasler JA, et al. (1995b). Low CYP1A2 activity in rural Shona children of Zimbabwe. Clin Pharmacol Ther 57:25–31
   PubMed Web of Science ®Google Scholar
• Masimirembwa C, Bertilsson L, Johansson I, et al. (1995a). Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther 57:656–661
   PubMed Web of Science ®Google Scholar
• Masimirembwa CM, Dandara C, Sommers DK, et al. (1998). Genetic polymorphism of cytochrome P4501A1, microsomal epoxide hydrolase, and glutathione S-transferases M1 and T1 in Zimbabweans and Venda of southern Africa. Pharmacogenetics 8:83--85
   PubMedGoogle Scholar
• Masimirembwa CM, Gustafsson LL, Dahl ML, et al. (1996b). Lack of effect of chloroquine on the debrisoquine (CYP2D6 and S-mephenytoin (CYP2C19) hydroxylation phenotypes. Br J Clin Pharmacol 41:344–346
   PubMed Web of Science ®Google Scholar
• Masimirembwa CM, Hasler JA. (1997). Genetic polymorphism of drug metabolising enzymes in African populations: Implications for the use of neuroleptics and antidepressants. Brain Res Bull 44:561–571
   PubMed Web of Science ®Google Scholar
• Masimirembwa CM, Johansson I, Hasler JA, Ingelman-Sundberg M. (1993). Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population. Pharmacogenetics 3:275–280
   PubMedGoogle Scholar
• Masimirembwa C, Persson I, Bertilsson L, et al. (1996a). A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: Association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol 42:713–719
   PubMed Web of Science ®Google Scholar
• Matimba A, Del-Favero J, Van Broeckhoven C, Masimirembwa C. (2009). Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects. Hum Genomics 3:169–190
   PubMedGoogle Scholar
• Matimba A, Oluka MN, Ebeshi BU, et al. (2008). Establishment of a biobank and pharmacogenetics database of African populations. Eur J Hum Genet 16:780–783
   PubMed Web of Science ®Google Scholar
• Mbanefo C, Bababunmi EA, Mahgoub A, et al. (1980). A study of the debrisoquine hydroxylation polymorphism in a Nigerian population. Xenobiotica 10:811–818
   PubMed Web of Science ®Google Scholar
• Mberu EK, Wansor T, Sato HA, et al. (1995). Japanese poor metabolizers of proguanil do not have an increased risk of malaria chemoprophylaxis breakthrough. Trans R Soc Trop Med Hyg 89:658–659
   PubMed Web of Science ®Google Scholar
• Mcdonagh EM, Wassenaar C, David SP, et al. (2012). PharmGKB summary: Very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6. Pharmacogenet Genomics 22:695–708
   PubMed Web of Science ®Google Scholar
• Mehlotra RK, Bockarie MJ, Zimmerman PA. (2007). CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: Implications for HIV/AIDS treatment. Br J Clin Pharmacol 64:391–395
   PubMed Web of Science ®Google Scholar
• Mehlotra RK, Ziats MN, Bockarie MJ, Zimmerman PA. (2006). Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea. Eur J Clin Pharmacol 62:267–275
   PubMed Web of Science ®Google Scholar
• Mitchell C, Gregersen N, Krause A. (2011). Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population. Pharmacogenomics 12:953–963
   PubMed Web of Science ®Google Scholar
• Miura J, Obua C, Abbo C, et al. (2009). Cytochrome P450 2C19 genetic polymorphisms in Ugandans. Eur J Clin Pharmacol 65:319–320
   PubMed Web of Science ®Google Scholar
• Mizutani T. (2003). PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev 35:99–106
   PubMed Web of Science ®Google Scholar
• Nakai K, Habano W, Nakai K, et al. (2005). Ethnic differences in CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) genotypes in Japanese and Israeli populations. Life Sci 78:107–111
   PubMed Web of Science ®Google Scholar
• Nakajima M, Komagata S, Fujiki Y, et al. (2007). Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenet Genomics 17:431–445
   PubMed Web of Science ®Google Scholar
• Nakajima M, Yokoi T, Mizutani M, et al. (1994). Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: Absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomarkers Prev 3:413–421
   PubMed Web of Science ®Google Scholar
• Nakajima M, Yoshida R, Fukami T, et al. (2004). Novel human CYP2A6 alleles confound gene deletion analysis. FEBS Lett 569:75–81
   PubMed Web of Science ®Google Scholar
• Naoe T, Takeyama K, Yokozawa T, et al. (2000). Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia. Clin Cancer Res 6:4091–4095
   PubMed Web of Science ®Google Scholar
• Nsabiyumva F, Furet Y, Autret E, et al. (1991). Oxidative polymorphism of dextromethorphan in a Burundi population. Eur J Clin Pharmacol 41:75–77
   PubMed Web of Science ®Google Scholar
• Nyakutira C, Roshammar D, Chigutsa E, et al. (2008). High prevalence of the CYP2B6 516G–>T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 64:357–365
   PubMed Web of Science ®Google Scholar
• Oliveira E, Pereira R, Amorim A, et al. (2009). Patterns of pharmacogenetic diversity in African populations: Role of ancient and recent history. Pharmacogenomics 10:1413–1422
   PubMed Web of Science ®Google Scholar
• Ouerhani S, Marrakchi R, Bouhaha R, et al. (2008). The role of CYP2D6*4 variant in bladder cancer susceptibility in Tunisian patients. Bull Cancer 95:E1–E4
   PubMedGoogle Scholar
• Paganotti GM, Gallo BC, Verra F, et al. (2011). Human genetic variation is associated with Plasmodium falciparum drug resistance. J Infect Dis 204:1772–1778
   PubMed Web of Science ®Google Scholar
• Paganotti GM, Gramolelli S, Tabacchi F, et al. (2012). Distribution of human CYP2C8*2 allele in three different African populations. Malar J 11:125
   PubMed Web of Science ®Google Scholar
• Panserat S, Sica L, Gerard N, et al. (1999). CYP2D6 polymorphism in a Gabonese population: Contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype. Br J Clin Pharmacol 47:121–124
   PubMed Web of Science ®Google Scholar
• Parathyras J, Gebhardt S, Hillermann-Rebello R, et al. (2009). A pharmacogenetic study of CD4 recovery in response to HIV antiretroviral therapy in two South African population groups. J Hum Genet 54:261–265
   PubMed Web of Science ®Google Scholar
• Parikh S, Ouedraogo JB, Goldstein JA, et al. (2007). Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: Implications for malaria treatment in Africa. Clin Pharmacol Ther 82:197–203
   PubMed Web of Science ®Google Scholar
• Paris PL, Kupelian PA, Hall JM, et al. (1999). Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev 8:901–905
   PubMed Web of Science ®Google Scholar
• Pavanello S, B'chir F, Pulliero A, et al. (2007). Interaction between CYP1A2-T2467DELT polymorphism and smoking in adenocarcinoma and squamous cell carcinoma of the lung. Lung Cancer 57:266–272
   PubMed Web of Science ®Google Scholar
• Penzak SR, Kabuye G, Mugyenyi P, et al. (2007). Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med 8:86–91
   PubMed Web of Science ®Google Scholar
• Perera MA, Gamazon E, Cavallari LH, et al. (2011). The missing association: Sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. Clin Pharmacol Ther 89:408–415
   PubMed Web of Science ®Google Scholar
• Persson I, Aklillu E, Rodrigues F, et al. (1996). S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics 6:521–526
   PubMedGoogle Scholar
• Phillips EJ, Mallal SA. (2008). Pharmacogenetics and the potential for the individualization of antiretroviral therapy. Curr Opin Infect Dis 21:16–24
   PubMed Web of Science ®Google Scholar
• Raimundo S, Toscano C, Klein K, et al. (2004). A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin Pharmacol Ther 76:128–138
   PubMed Web of Science ®Google Scholar
• Ribaudo HJ, Haas DW, Tierney C, et al. (2006). Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: An Adult AIDS Clinical Trials Group Study. Clin Infect Dis 42:401–407
   PubMed Web of Science ®Google Scholar
• Rodriguez-Antona C, Sayi JG, Gustafsson LL, et al. (2005). Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem Biophys Res Commun 338:299–305
   PubMed Web of Science ®Google Scholar
• Rosemary J, Adithan C. (2007). The pharmacogenetics of CYP2C9 and CYP2C19: Ethnic variation and clinical significance. Curr Clin Pharmacol 2:93–109
   PubMedGoogle Scholar
• Rotger M, Telenti A. (2008). Optimizing efavirenz treatment: CYP2B6 genotyping or therapeutic drug monitoring? Eur J Clin Pharmacol 64:335–336
   PubMed Web of Science ®Google Scholar
• Rower S, Bienzle U, Weise A, et al. (2005). Short communication: High prevalence of the cytochrome P450 2C8*2 mutation in Northern Ghana. Trop Med Int Health 10:1271–1273
   PubMed Web of Science ®Google Scholar
• Roy JN, Lajoie J, Zijenah LS, et al. (2005). CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab Dispos 33:884–887
   PubMed Web of Science ®Google Scholar
• Sachse C, Brockmöller J, Bauer S, Roots I. (1999). Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47:445–449
   PubMed Web of Science ®Google Scholar
• Santovito A, Burgarello C, Cervella P, Delpero M. (2010). Polymorphisms of cytochrome P450 1A1, glutathione s-transferases M1 and T1 genes in Ouangolodougou (Northern Ivory Coast). Genet Mol Biol 33:434–437
   PubMed Web of Science ®Google Scholar
• Schoch GA, Yano JK, Wester MR, et al. (2004). Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site. J Biol Chem 279:9497–9503
   PubMed Web of Science ®Google Scholar
• Schoedel KA, Hoffmann EB, Rao Y, et al. (2004). Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 14:615–626
   PubMedGoogle Scholar
• Scordo MG, Aklillu E, Yasar U, et al. (2001). Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol 52:447–450
   PubMed Web of Science ®Google Scholar
• Scott SA, Jaremko M, Lubitz SA, et al. (2009). CYP2C9*8 is prevalent among African-Americans: Implications for pharmacogenetic dosing. Pharmacogenomics 10:1243–1255
   PubMed Web of Science ®Google Scholar
• Scott SA, Sangkuhl K, Gardner EE, et al. (2011). Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 90:328–332
   PubMed Web of Science ®Google Scholar
• Shastry BS. (2006). Pharmacogenetics and the concept of individualized medicine. Pharmacogenomics J 6:16–21
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Mimura M, et al. (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–423
   PubMed Web of Science ®Google Scholar
• Shrif NE, Won HH, Lee ST, et al. (2011). Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients. Eur J Clin Pharmacol 67:1119–1130
   PubMed Web of Science ®Google Scholar
• Sibbing D, Koch W, Gebhard D, et al. (2010a). Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 121:512–518
   PubMed Web of Science ®Google Scholar
• Sibbing D, Steinhubl SR, Schulz S, et al. (2010b). Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: Initial evidence of a therapeutic window. J Am Coll Cardiol 56:317–318
   PubMed Web of Science ®Google Scholar
• Sim SC, Risinger C, Dahl ML, et al. (2006). A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103–113
   PubMed Web of Science ®Google Scholar
• Simooya OO, Njunju E, Hodjegan AR, et al. (1993). Debrisoquine and metoprolol oxidation in Zambians: A population study. Pharmacogenetics 3:205--208
   PubMedGoogle Scholar
• Simooya OO, Sijumbil G, Lennard MS, Tucker GT. (1998). Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians. Br J Clin Pharmacol 45:315–317
   PubMed Web of Science ®Google Scholar
• Sirugo G, Hennig BJ, Adeyemo AA, et al. (2008). Genetic studies of African populations: An overview on disease susceptibility and response to vaccines and therapeutics. Hum Genet 123:557–598
   PubMed Web of Science ®Google Scholar
• Sistonen J, Fuselli S, Palo JU, et al. (2009). Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet Genomics 19:170–179
   PubMed Web of Science ®Google Scholar
• Sistonen J, Sajantila A, Lao O, et al. (2007). CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 17:93–101
   PubMed Web of Science ®Google Scholar
• Skjelbo E, Mutabingwa TK, Bygbjerg I, et al. (1996). Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians. Clin Pharmacol Ther 59:304–311
   PubMed Web of Science ®Google Scholar
• Solus JF, Arietta BJ, Harris JR, et al. (2004). Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 5:895–931
   PubMed Web of Science ®Google Scholar
• Sommers DK, Moncrieff J, Avenant J. (1988). Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa. Hum Toxicol 7:273–276
   PubMedGoogle Scholar
• Sommers DK, Moncrieff J, Avenant J. (1989a). Metoprolol alpha-hydroxylation polymorphism in the San Bushmen of southern Africa. Hum Toxicol 8:39–43
   PubMedGoogle Scholar
• Sommers DK, Moncrieff J, Avenant J. (1989b). Non-correlation between debrisoquine and metoprolol polymorphisms in the Venda. Hum Toxicol 8:365–368
   PubMedGoogle Scholar
• Sommers DK, Moncrieff J, Avenant J. (1990). Polymorphism in sparteine oxidation in the Barakwena (Kwengo) of Southern Africa. South Afr J Sci 86:28--29
   Web of Science ®Google Scholar
• Sommers DK, Moncrieff J, Avenant JC. (1991). Absence of polymorphism of sparteine oxidation in the South African Venda. Hum Exp Toxicol 10:175–178
   PubMed Web of Science ®Google Scholar
• Suarez-Kurtz G. (2011). Linkage disequilibrium between the CYP2C19*17 and CYP2C8*2 alleles in populations of African descent. Eur J Clin Pharmacol 67:211–212
   PubMed Web of Science ®Google Scholar
• Swart M, Skelton M, Wonkam A, et al. (2012). CYP1A2, CYP2A6, CYP2B6, CYP3A4 and CYP3A5 polymorphisms in two Bantu-speakiing populations from Cameroon and South Africa: Implications for global pharmacogenetics. Curr Pharmacogen Pers Med 10:43--53
   Google Scholar
• Tang YM, Green BL, Chen GF, et al. (2000). Human CYP1B1 Leu432Val gene polymorphism: Ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. Pharmacogenetics 10:761–766
   PubMedGoogle Scholar
• Tang YM, Wo YY, Stewart J, et al. (1996). Isolation and characterization of the human cytochrome P450 CYP1B1 gene. J Biol Chem 271:28324–28330
   PubMed Web of Science ®Google Scholar
• Tayeb MT, Clark C, Ameyaw MM, et al. (2000). CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations. Pharmacogenetics 10:753–756
   PubMedGoogle Scholar
• Telenti A, Zanger UM. (2008). Pharmacogenetics of anti-HIV drugs. Annu Rev Pharmacol Toxicol 48:227–256
   PubMed Web of Science ®Google Scholar
• Thompson EE, Kuttab-Boulos H, Witonsky D, et al. (2004). CYP3A variation and the evolution of salt-sensitivity variants. Am J Hum Genet 75:1059–1069
   PubMed Web of Science ®Google Scholar
• Tishkoff SA, Kidd KK, et al. (2004). Implications of biogeography of human populations for race and medicine. Nat Genet 36:S21–S27
   PubMed Web of Science ®Google Scholar
• Tishkoff SA, Reed FA, Friedlaender FR, et al. (2009). The genetic structure and history of Africans and African Americans. Science 324:1035–1044
   PubMed Web of Science ®Google Scholar
• Tishkoff SA, Verrelli BC. (2003a). Patterns of human genetic diversity: Implications for human evolutionary history and disease. Annu Rev Genomics Hum Genet 4:293–340
   PubMed Web of Science ®Google Scholar
• Tishkoff SA, Verrelli BC. (2003b). Role of evolutionary history on haplotype block structure in the human genome: Implications for disease mapping. Curr Opin Genet Dev 13:569–575
   PubMed Web of Science ®Google Scholar
• Tishkoff SA, Williams SM. (2002). Genetic analysis of African populations: Human evolution and complex disease. Nat Rev Genet 3:611–621
   PubMed Web of Science ®Google Scholar
• Tsuchiya K, Gatanaga H, Tachikawa N, et al. (2004). Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun 319:1322–1326
   PubMed Web of Science ®Google Scholar
• Tyndale RF, Droll KP, Sellers EM. (1997). Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Pharmacogenetics 7:375–379
   PubMedGoogle Scholar
• Vasiliou V, Gonzalez FJ. (2008). Role of CYP1B1 in glaucoma. Annu Rev Pharmacol Toxicol 48:333–358
   PubMed Web of Science ®Google Scholar
• Walker AH, Jaffe JM, Gunasegaram S, et al. (1998). Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: Ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online. Hum Mutat 12:289 (abstract)
   Google Scholar
• Wan YJ, Poland RE, Han G, et al. (2001). Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in southern California. Pharmacogenetics 11:489–499
   PubMedGoogle Scholar
• Wandel C, Witte JS, Hall JM, et al. (2000). CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B5′-promoter region polymorphism. Clin Pharmacol Ther 68:82–91
   PubMed Web of Science ®Google Scholar
• Wang D, Guo Y, Wrighton SA, et al. (2011). Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J 11:274–286
   PubMed Web of Science ®Google Scholar
• Wang XL, Raveendran M, Wang J. (2003). Genetic influence on cigarette-induced cardiovascular disease. Prog Cardiovasc Dis 45:361–382
   PubMed Web of Science ®Google Scholar
• Wang J, Sonnerborg A, Rane A, et al. (2006). Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics 16:191–198
   PubMed Web of Science ®Google Scholar
• Watkins PB. (1990). Role of cytochromes P450 in drug metabolism and hepatotoxicity. Semin Liver Dis 10:235–250
   PubMed Web of Science ®Google Scholar
• Weinshilboum R. (2003). Inheritance and drug response. N Engl J Med 348:529–537
   PubMed Web of Science ®Google Scholar
• Wennerholm A, Johansson I, Hidestrand M, et al. (2001). Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity. Pharmacogenetics 11:417–427
   PubMedGoogle Scholar
• Wennerholm A, Johansson I, Massele AY, et al. (1999). Decreased capacity for debrisoquine metabolism among black Tanzanians: Analyses of the CYP2D6 genotype and phenotype. Pharmacogenetics 9:707–714
   PubMedGoogle Scholar
• Wojnowski L, Turner PC, Pedersen B, et al. (2004). Increased levels of aflatoxin-albumin adducts are associated with CYP3A5 polymorphisms in The Gambia, West Africa. Pharmacogenetics 14:691–700
   PubMedGoogle Scholar
• Woolhouse NM, Andoh B, Mahgoub A, et al. (1979). Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians. Clin Pharmacol Ther 26:584–591
   PubMed Web of Science ®Google Scholar
• Woolhouse NM, Eichelbaum M, Oates NS, et al. (1985). Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians. Clin Pharmacol Ther 37:512–521
   PubMed Web of Science ®Google Scholar
• Wright GE, Niehaus DJ, Drogemoller BI, et al. (2010). Elucidation of CYP2D6 genetic diversity in a unique African population: Implications for the future application of pharmacogenetics in the Xhosa population. Ann Hum Genet 74:340–350
   PubMed Web of Science ®Google Scholar
• Xie HJ, Yasar U, Lundgren S, et al. (2003). Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J 3:53–61
   PubMed Web of Science ®Google Scholar
• Yasar U, Aklillu E, Canaparo R, et al. (2002). Analysis of CYP2C9*5 in Caucasian, Oriental and black-African populations. Eur J Clin Pharmacol 58:555–558
   PubMed Web of Science ®Google Scholar
• Yen-Revollo JL, Van Booven DJ, Peters EJ, et al. (2009). Influence of ethnicity on pharmacogenetic variation in the Ghanaian population. Pharmacogenomics J 9:373–379
   PubMed Web of Science ®Google Scholar
• Zanger UM, Raimundo S, Eichelbaum M. (2004). Cytochrome P450 2D6: Overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 369:23–37
   PubMed Web of Science ®Google Scholar
• Zeigler-Johnson CM, Walker AH, Mancke B, et al. (2002). Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Hum Hered 54:13–21
   PubMed Web of Science ®Google Scholar
• Zhou K, Donnelly L, Burch L, et al. (2010a). Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: A Go-DARTS study. Clin Pharmacol Ther 87:52–56
   PubMed Web of Science ®Google Scholar
• Zhou SF. (2009). Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part II. Clin Pharmacokinet 48:761–804
   PubMed Web of Science ®Google Scholar
• Zhou SF, Liu JP, Chowbay B. (2009). Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41:89–295
   PubMed Web of Science ®Google Scholar
• Zhou SF, Zhou ZW, Huang M. (2010b). Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology 278:165–188
   PubMed Web of Science ®Google Scholar